Initial Treatment With Golimumab in Early PsA

golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks

Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.